Kedrion S.p.A.

Serious concerns about manufacturing quality extended the US Food and Drug Administration’s fast-track review of Prometic Biotherapeutics Inc.’s designated orphan drug, Ryplazim (plasminogen, human-

The US Food and Drug Administration is starting off the summer with an array of approvals in historically less-active development areas like women’s health and obesity – along with the ninth novel onc

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker . Menarini To Pay $11.50 Per Share In

The US Food and Drug Administration has devised a development pathway to support the approval of monoclonal antibodies for use in rabies post-exposure prophylaxis (PEP) as an alternative to anti-rabie